Safety of chinese herbal medicine for XXXX .

@entity1 @entity1296 @entity390 @entity2133 @entity1030 @entity1058
@entity1058 ( @entity1058 ) is increasingly used by @entity1 with @entity1030 ( @entity1030 ); however, there has been no systematic evaluation of its safety. This review examined the adverse events (AEs) reported in clinical studies of @entity1058 for @entity1030 . Five English databases (PubMed, Embase, CINAHL, AMED, and CENTRAL) and four Chinese databases (CBM, CNKI, CQVIP, and Wanfang Data) were searched from inception to May 2013. Adverse event data, including nature, severity, author-assigned causality, management, and outcome, were extracted from included studies. Descriptive statistics were used for the rate of adverse events. Of the 152 included studies, AEs were reported in 47 studies. The rate of adverse events was slightly lower in the @entity1058 groups compared with controls (84 events in 5,909 @entity1 , 1.4% versus 102 events in 5,676 @entity1 , 1.8%). The most frequently reported adverse event was @entity390 (28 cases in the @entity1058 groups and 19 cases in the control groups), which was more common in studies where @entity1058 was combined with pharmacotherapy to treat acute exacerbation of @entity1030 . Other frequent adverse events were abdominal discomfort, @entity2133 , and @entity1296 . Detailed information about the adverse events was scant. Overall, @entity1058 appears to be well tolerated in @entity1 with @entity1030 .
